tiprankstipranks
Advertisement
Advertisement
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
PremiumRatingsResmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
20d ago
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
Premium
Company Announcements
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan
28d ago
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144
Premium
Company Announcements
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144
1M ago
ResMed Chairman Emeritus Peter Farrell Sells Shares Under 10b5-1 Plan
PremiumCompany AnnouncementsResMed Chairman Emeritus Peter Farrell Sells Shares Under 10b5-1 Plan
2M ago
ResMed General Counsel Sells Shares Under Pre-Set Trading Plan
Premium
Company Announcements
ResMed General Counsel Sells Shares Under Pre-Set Trading Plan
2M ago
ResMed Adjusts CDI and Share Balances Amid Ongoing Capital Management
Premium
Company Announcements
ResMed Adjusts CDI and Share Balances Amid Ongoing Capital Management
2M ago
ResMed price target raised to $302 from $299 at KeyBanc
PremiumThe FlyResMed price target raised to $302 from $299 at KeyBanc
2M ago
ResMed price target raised to $265 from $260 at Stifel
Premium
The Fly
ResMed price target raised to $265 from $260 at Stifel
2M ago
ResMed price target raised to $281 from $275 at Baird
Premium
The Fly
ResMed price target raised to $281 from $275 at Baird
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100